Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
Eli Lilly’s $7 billion acquisition of in vivo CAR-T developer Kelonia Therapeutics, announced April 21, 2026, marks the highest-valuation deal in the next-generation cell therapy segment to date, accelerating large pharma’s pivot away from complex ex vivo CAR-T offerings currently dominated by Gilea
Gilead Sciences (GILD) - Bullish Catalysts Emerge Amid Big Pharma's $7B In Vivo CAR-T Deal Wave - Post Earnings
GILD - Stock Analysis
3522 Comments
1442 Likes
1
Jeweldean
Regular Reader
2 hours ago
Indices are showing resilience amid macroeconomic uncertainty.
👍 260
Reply
2
Derez
Trusted Reader
5 hours ago
This is exactly what I was looking for last night.
👍 199
Reply
3
Raelah
Elite Member
1 day ago
Indices continue to test resistance and support zones, providing key levels for trading decisions.
👍 210
Reply
4
Arcelio
Loyal User
1 day ago
Overall market momentum is stable, though sector-specific risks remain present.
👍 289
Reply
5
Caycee
Consistent User
2 days ago
I’d pay to watch you do this live. 💵
👍 221
Reply
© 2026 Market Analysis. All data is for informational purposes only.